Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 39 - Medicinal preparations containing antigens or antibodies
Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
10/2013
10/22/2013CA2412626C Il-17 molecules and uses thereof
10/22/2013CA2359926C Antagonists of hmg1 for treating inflammatory conditions
10/17/2013WO2013155512A2 Treatment of ischemic retinopathies
10/17/2013WO2013155447A1 Tiki inhibitors
10/17/2013WO2013155441A1 Filovirus consensus antigens, nucleic acid constructs and vaccines made therefrom, and methods of using same
10/17/2013WO2013155406A1 Contragestion and treating inflammation by modulating sodium channel activity in the epithelium
10/17/2013WO2013155320A2 Use of microbial gene products to prevent or treat microbial infections
10/17/2013WO2013155010A1 Non-invasive biomarkers for eosinophilic esophagitis
10/17/2013WO2013154728A1 Genetically stable live attenuated respiratory syncytial virus vaccine and its production
10/17/2013WO2013154206A1 Anti-fgfr2 antibody
10/17/2013WO2013153372A1 Bacterial vaccine
10/17/2013WO2013153179A1 Liposomes containing oligopeptide fragments of myelin basic protein, a pharmaceutical composition and a method for treatment of multiple sclerosis
10/17/2013WO2013104995A3 Compositions and methods for treating viral infections
10/17/2013WO2013081571A3 Isolated lyssavirus nucleic acid and protein sequences
10/17/2013WO2013040472A8 Compositions and methods related to dna damage repair
10/17/2013WO2013029033A8 Rotavirus preparations with excess calcium ions and high viscosities that ensure vaccine viability at elevated temperatures
10/17/2013WO2012156018A8 Antibodies for treatment of cancer expressing claudin 6
10/17/2013WO2012096994A3 Antibodies directed against influenza
10/17/2013US20130274175 Treatment of disease associated with the use of antibiotics
10/17/2013US20130274172 Single domain tdf-related compounds and analogs thereof
10/17/2013US20130274133 Genetic variations in the interleukin-6 receptor gene as predictors of the response of patients to treatment with interleukin-6 receptor inhibitors
10/17/2013US20130273170 Puumala virus full-length m segment-based dna vaccines
10/17/2013US20130273150 Dendritic Cell Marker and Uses Thereof
10/17/2013US20130273149 Disaccharide synthetic lipid compounds and uses thereof
10/17/2013US20130273148 Norovirus vaccine formulations
10/17/2013US20130273147 Method of conferring a protective immune response to norovirus
10/17/2013US20130273144 Phospholipid drug analogs
10/17/2013US20130273120 Methods and compositions for intranasal delivery
10/17/2013US20130273113 Immunogenic apoptosis inducing compositions and methods of use thereof
10/17/2013US20130273112 Consensus antigen constructs and vaccines made therefrom, and methods of using the same to treat malaria
10/17/2013US20130273110 Tuberculosis Vaccine And Method Of Using Same
10/17/2013US20130273109 Method for generating a parvovirus b19 virus-like particle
10/17/2013US20130273108 Compositions and methods for vaccinating against hsv-2
10/17/2013US20130273107 Compositions and methods for vaccinating against hsv-2
10/17/2013US20130273105 Norovirus vaccine formulations
10/17/2013US20130273104 Adjuvanted Influenza Vaccines for Pediatric Use
10/17/2013US20130273102 Parenteral norovirus vaccine formulations
10/17/2013US20130273101 Vaccine for inducing an improved immune reaction
10/17/2013US20130273100 Vaccines with live bacterial isolates for systemic administration
10/17/2013US20130273099 Prevention and treatment of sub-clinical pcvd
10/17/2013US20130273098 Novel formulations which mitigate agitation-induced aggregation of immunogenic compositions
10/17/2013US20130273095 Vaccine composition for controlling ectoparasite infestations
10/17/2013US20130273094 Vaccines against toxoplasma gondii
10/17/2013US20130273093 Method for Immunising a Subject against Mycobacterium Tuberculosis or Mycobacterium Bovis
10/17/2013US20130273092 Uses of yersinia yope peptide, gene and subparts thereof as a plague vaccine component and assays for yersinia pestis-specific t cells
10/17/2013US20130273091 Immunogenic compositions
10/17/2013US20130273089 Antibody and methods for selective inhibition of t-cell responses
10/17/2013US20130273086 Compositions And Methods For Treatment, Research And Therapeutic Applications For Malaria
10/17/2013US20130273082 Trisaccharide derivates, and their use as adjuvants
10/17/2013US20130273078 Synergistic anti-tumor efficacy using alloantigen combination immunotherapy
10/17/2013US20130273075 Compounds and Method for Modulating Inflammatory Reactions
10/17/2013US20130273074 Methods and Compositions Using Anti-LPS Ligands for the Treatment and Prevention of Inflammatory Disorders
10/17/2013US20130273071 Recombinant IL-9 Antibodies And Uses Thereof
10/17/2013US20130273070 Methods for treating or preventing influenza virus infection by administering a serine protease inhibitor
10/17/2013US20130273069 Pcsk9 antagonists
10/17/2013US20130273067 Self-Buffering Protein Formulations
10/17/2013US20130273066 Self-Buffering Protein Formulations
10/17/2013US20130273065 Therapeutic Compositions For Treatment Of Inflammation Of Ocular And Adnexal Tissues
10/17/2013US20130273061 Combination therapy
10/17/2013US20130273057 Methods and compositions for the treatment and diagnosis of vascular inflammatory disorders or endothelial cell disorders
10/17/2013US20130273056 Tyrosine-phosphorylated wbp2, a novel cancer target and biomarker
10/17/2013US20130273053 Compositions and Methods of Inhibiting MASP-1 and/or MASP-2 and/or MASP-3 for the Treatment of Paroxysmal Nocturnal Hemoglobinuria
10/17/2013US20130273052 Polypeptides that bind to human complement component c5
10/17/2013US20130273050 Pharmaceutical compositions with resistance to soluble cea
10/17/2013US20130273048 Stabilizing agent and blocking agent
10/17/2013US20130273047 Clotting Factor-Fc Chimeric Proteins to Treat Hemophilia
10/17/2013US20130273046 Preparation of isolated agonist anti-edar monoclonal antibodies
10/17/2013US20130273042 Treatment of multiple sclerosis
10/17/2013US20130273041 Use of chimeric anti-cd20 antibody as in vitro or in vivo purging agent in patients receiving bmt or pbsc transplant
10/17/2013US20130273039 Combination therapies for b-cell lymphomas comprising administration of anti-cd20 antibody
10/17/2013US20130273038 Human cdr-grafted antibody and antibody fragment thereof
10/17/2013US20130273035 Methods and Compositions for Reducing Amyloid Beta Levels
10/17/2013US20130273032 Predictive biomarker for cancer treatment with adcc-enhanced antibodies
10/17/2013US20130273030 Use of inhibitors of bruton's tyrosine kinase (btk)
10/17/2013US20130273029 Antibodies for epidermal growth factor receptor 3 (her3) directed to domain ii of her3
10/17/2013US20130273002 Multivalent breast cancer vaccine
10/17/2013US20130273001 Immunostimulation by chemically modified rna
10/17/2013US20130272968 Neutralizing prolactin receptor antibodies and their therapeutic use
10/17/2013US20130272964 Molecules with extended half-lives, compositions and uses thereof
10/16/2013EP2650369A1 Novel synthetic agonists of TLR9
10/16/2013EP2650368A1 Nucleic acid of formula (I): GlXmGn, or (II): ClXmCn, in particular as an immune-stimulating agent/adjuvant
10/16/2013EP2650367A1 Human monoclonal antibody
10/16/2013EP2650362A2 Novel vaccines against the a/h1n1 pandemic flu virus
10/16/2013EP2650309A1 Conjugate of folate and antibody, preparation method and use thereof
10/16/2013EP2650308A2 Use of anti-amyloid beta antibody in ocular diseases
10/16/2013EP2650306A1 Humanized Anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
10/16/2013EP2650020A1 Trimeric OX40-immunoglobulin fusion protein and methods of use
10/16/2013EP2650018A2 Antibody-LIGHT fusion products for cancer therapeutics
10/16/2013EP2650017A2 Alpha 5 - beta 1 antibodies and their uses
10/16/2013EP2650016A1 Human antibodies to PSCK9 for use in methods of treatment based on particular dosage regimens (11565)
10/16/2013EP2650015A2 Compositions and methods of use of ORF 554 from beta hemolytic Streptococcal strains
10/16/2013EP2650014A2 Compositions and methods of use of ORF1358 from beta-hemolytic streptococcal strains
10/16/2013EP2649995A2 Inhibition of post-radiation tumor growth
10/16/2013EP2649990A1 Compositions with reduced dimer formation
10/16/2013EP2649098A1 Antibodies against ror1 and uses thereof
10/16/2013EP2649097A1 Anti ccr4 antibodies and uses thereof
10/16/2013EP2649086A1 Use of chimeric antigen receptor-modified t cells to treat cancer
10/16/2013EP2648754A2 Methods of inhibiting metastasis from cancer
10/16/2013EP2648753A2 Dosage and administration of bispecific scfv conjugates
10/16/2013EP2648752A2 Humanized antibodies to liv-1 and use of same to treat cancer
1 ... 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 131 ... 1823